Kimball Electronics Q4 FY26 slides: medical drives growth despite profit miss
Kimball Electronics (NASDAQ:KE) reported fiscal Q4 2026 revenue of $372M, about on target, down 2% year over year. Adjusted EPS was -$0.01 vs $0.41 expected, with adjusted operating income $18.1M. Medical sales rose to $109M, while cash flow and debt fell. Fiscal 2027 revenue guidance is $1.535B to $1.560B.
How this was made
The 30-second read
Why it matters
Traders should focus on the combination of (1) the adjusted EPS miss, (2) FY27 revenue growth guidance supported by Helvoet and medical, and (3) explicit near-term margin drag from the Indianapolis CDMO facility ramp.
Market read
A company-specific earnings miss paired with quantified FY27 growth and margin headwinds creates a tradable setup for repricing near-term profitability versus longer medical growth.
What to watch
Facility-related costs are quantified for FY27, but the article does not provide updated gross margin trajectory beyond the quarter, leaving uncertainty around how quickly the Indianapolis ramp normalizes margins.
Background
Kimball Electronics’ FY26 Q4 results show stabilization in the base business and continued medical vertical momentum, alongside a profitability setback.
Ticker impact
Kimball Electronics reported adjusted EPS of -$0.01 vs $0.41 consensus, while revenue was $372M, and guided FY27 revenue $1.535B-$1.560B.
Near-term downside risk from the adjusted EPS miss, partially offset by FY27 revenue growth and medical segment strength; margin guidance could cap upside.
The article provides both the miss (adjusted EPS) and forward-looking drivers (medical growth, Helvoet contribution, and $6.5M-$7.0M facility cost drag), which are the key inputs for repricing expectations.
Market effects
Highlights margin pressure risk during medical CDMO capacity buildouts, which can influence how investors price EMS/CDMO peers’ near-term profitability.
Medical sales mix is shifting toward Asia and Europe, which may affect regional demand expectations for medical device and diagnostics manufacturing.
No direct global macro linkage beyond the company’s international revenue diversification and tax resolution impacts.
Counterpoint
The adjusted EPS miss may be disproportionately driven by elevated S&A and a one-off tax resolution, while cash flow and medical growth remain strong.
Key entities
- companyKimball Electronics
Reported FY26 Q4 results with an adjusted EPS miss, medical segment growth, and FY27 guidance including margin pressure from a new CDMO facility.
- executiveRic Phillips
CEO cited base business stabilization and medical-led organic growth.
- executiveJana Croom
CFO emphasized balance sheet strength and cash generation.
- acquisition_targetHelvoet Polymer Technologies
Acquisition closed July 1, 2026, expected to contribute about $60M revenue in FY27.
- projectIndianapolis medical CDMO facility
Production equipment installation underway, qualification begins fall 2026, early production expected end of calendar 2026; FY27 facility costs expected to reduce earnings by $6.5M-$7.0M.
